PNPLA3 and Cirrhosis: Moreover, a recent analysis of data from two independent cohorts (7893 and 46,880 participants, respectively) indicated that the PNPLA3-rs738409-GG had additive effects with metabolic risk factors, such as diabetes and obesity: carriers of this genotype with an indeterminate risk of fibrosis (FIB-4 score between 1.3 and 2.67) and diabetes had a similar incidence rate of cirrhosis as patients with a high risk of fibrosis (FIB-4 > 2.67) [66].